• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    (TSV:TELO)

    0.0550 UNCHANGED
    Streaming Delayed Price Updated: 2:02 PM EDT, Oct 30, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about TELO

    OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference
    From Virtual Investor Conferences
    Via GlobeNewswire
    OTCQB Venture Virtual Investor Conference Agenda Announced for August 7th
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
    Toronto, Ontario--(Newsfile Corp. - October 26, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce... 
    Via Newsfile
    Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
    EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
    EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study
    Toronto, Ontario--(Newsfile Corp. - September 14, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is... 
    Via Newsfile
    Telo Genomics Announces Full-Services Investor Relations Agreement with Adelaide Capital
    Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to... 
    Via Newsfile
    Topics Artificial Intelligence
    Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
    From FN Media Group LLC
    Via GlobeNewswire
    Telo Genomics Participates in the 18th International Myeloma Society Workshop 2021
    Toronto, Ontario--(Newsfile Corp. - September 9, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to... 
    Via Newsfile
    Topics Artificial Intelligence
    Telo Genomics Engages Clinical and Regulatory Affairs Veteran to Lead the Company's ISO 15189 Certification & CLIA Laboratory Accreditation Undertaking
    Toronto, Ontario--(Newsfile Corp. - August 9, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to... 
    Via Newsfile
    Topics Artificial Intelligence
    Telo Genomics Completes First Tranche of Oversubscribed Private Placement
    Toronto, Ontario--(Newsfile Corp. - July 2, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") announces that it... 
    Via Newsfile
    Topics Artificial Intelligence
    Telo Genomics Announces Co-Authored Publication of a Prospective 5-year Multiple Myeloma Study - Successfully Identifying High Risk versus Low Risk Smoldering Myeloma Patients
    Toronto, Ontario--(Newsfile Corp. - April 29, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to... 
    Via Newsfile
    Topics Artificial Intelligence
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.